A Crohn’s gut-exam score fell an average 47.5% in five people after 14 days. The study had no placebo group.
Palisade Bio presented clinical findings at the ACG 2026 Annual Meeting. PALI-2108 showed early clinical activity in UC and Crohn's patients, with mean score reductions of 62.8% and 47.5% respectively. The company is advancing Phase 2 trials for both indications. According to the company, the findings support the drug's mechanism and delivery platform.
How this was made
The 30-second read
Why it matters
The presented data provide mechanistic and clinical proof‑of‑concept, potentially de‑risking the upcoming Phase 2 program.
Market read
First‑time disclosure of early efficacy in Crohn's disease could move the stock ahead of the Phase 2 launch.
What to watch
Concurrent biologic therapy in patients could confound efficacy signals.
Background
Palisade Bio is a clinical‑stage company developing oral, gut‑targeted PDE4 inhibitor prodrugs for inflammatory bowel diseases.
Ticker impact
Palisade Bio presented Phase 1/1b data showing 47.5% reduction in SES‑CD score and target engagement for its PDE4 inhibitor PALI‑2108.
likely upward pressure as investors price in promising efficacy signals
Data are first‑time disclosures, show clear biomarker and endoscopic improvements, and are directly tied to the company's lead asset.
Market effects
May boost sentiment for oral PDE4 inhibitor programs and IBD biotech sector.
Limited to US biotech investors; no broader regional effect.
Relevant to global IBD therapeutic pipeline investors.
Counterpoint
Early‑phase data are small and open‑label; efficacy may not translate to larger Phase 2 trials.
Key entities
- companyPalisade Bio, Inc.
Developer of PALI‑2108, an oral PDE4 inhibitor prodrug.
- executiveMitch Jones, M.D., Ph.D.
President and Chief Medical Officer of Palisade Bio.
